In the process to finally unravel the mysteries of prostate cancer and even develop a blood test that can help doctors plan treatment options in the early stages, five new gene variants, or mutations have been linked to the aggressive and deadly disease. Meet LEPR, CRY1, RNASEL, IL4 and ARVCF.
For this particular study, scientists, always looking for genetic differences that could highlight risk differences, gathered blood samples from more than 1,300 prostate cancer patients living in the Seattle region. All were between the ages of 35 and 74 when diagnosed.
What they came up with were five single letter mutations (SNPs) that were isolated among the patients' "DNA alphabet" as having a significant bearing on prostate cancer progression in terms of affecting cell death, tumor growth, inflammation, androgen hormone levels, blood-vessel development and bone density.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment